Markers for predicting the efficacy of beta-blockers in vasovagal syncope management in children: A mini-review

Jing Wang; Xueqin Liu; Hongfang Jin; Junbao Du

doi:10.3389/fcvm.2023.1131967

Markers for predicting the efficacy of beta-blockers in vasovagal syncope management in children: A mini-review

Front Cardiovasc Med. 2023 Mar 8:10:1131967. doi: 10.3389/fcvm.2023.1131967. eCollection 2023.

Authors

Jing Wang¹, Xueqin Liu¹, Hongfang Jin¹, Junbao Du^{1

2}

Affiliations

¹ Department of Pediatrics, Peking University First Hospital, Beijing, China.
² Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.

Abstract

Vasovagal syncope (VVS) is a common subtype of neurally mediated syncope. It is prevalent in children and adolescents, and critically affects the quality of life of patients. In recent years, the management of pediatric patients with VVS has received extensive attention, and β-blocker serves as an important choice of the drug therapy for children with VVS. However, the empirical use of β-blocker treatment has limited therapeutic efficacy in patients with VVS. Therefore, predicting the efficacy of β-blocker therapy based on biomarkers related to the pathophysiological mechanism is essential, and great progress has been made by applying these biomarkers in formulating individualized treatment plans for children with VVS. This review summarizes recent advances in predicting the effect of β-blockers in the management of VVS in children.

Keywords: beta-adrenergic receptor blockers; children; individualized management; prediction; vasovagal syncope.

Publication types

Review

Grants and funding

The manuscript was supported by the National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital, China) (2022CR59).